Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation
Kailera Therapeutics Inc KLRA
$11.22
▼ -6.39%
($-0.77)
📉 Near 52W Low
⬇️ Below Yest. Low
Open
$11.80
Prev Close
$11.98
Day Range
$11.10 – $12.33
52W Range
$11.77 – $28.23
Market Cap
$1.45B
Beta
2.41
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-04-17 |
| Shares Out. | 129,570,000 |
| Website | kailera.com ↗ |
| Phone | 15084409475 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$111.3M |
| Total Assets | $1.21B |
| Total Liabilities | $93.0M |
| Equity | $1.12B |
About Kailera Therapeutics Inc
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Kailera Therapeutics Inc is a publicly traded company under the ticker symbol KLRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)